Research programme: lung disorders therapy - Emergent BioDefense Operations Lansing/University of Maryland

Drug Profile

Research programme: lung disorders therapy - Emergent BioDefense Operations Lansing/University of Maryland

Alternative Names: Research programme: mucin release inhibitors - Emergent BioDefense Operations Lansing/University of Maryland; Research programme: polycationic peptides - Emergent BioDefense Operations Lansing/University of Maryland

Latest Information Update: 01 May 2007

Price : $50

At a glance

  • Originator University of Maryland, Baltimore
  • Developer Emergent BioDefense Operations Lansing; University of Maryland, Baltimore
  • Class
  • Mechanism of Action Mucin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma; Bronchiectasis; Bronchitis; Cystic fibrosis

Most Recent Events

  • 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
  • 14 Nov 2002 This programme is still in active development
  • 06 Oct 2000 Preclinical development for Asthma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top